Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
1.
J Immunol Res ; 2021: 6629824, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34222496

RESUMEN

Haemophilus influenzae is a common organism of the human upper respiratory tract; this bacterium is responsible of a wide spectrum for respiratory infections and can generate invasive diseases such as meningitis and septicemia. These infections are associated with H. influenzae encapsulated serotype b. However, the incidence of invasive disease caused by nontypeable H. influenzae (NTHi) has increased in the post-H. influenzae serotype b (Hib) vaccine era. Currently, an effective vaccine against NTHi is not available; due to this, it is important to find an antigen capable to confer protection against NTHi infection. In this study, 10 linear B cell epitopes and 13 CTL epitopes and a putative plasminogen-binding motif (252FYNKENGMY260) and the presence of enolase on the surface of different strains of H. influenzae were identified in the enolase sequence of H. influenzae. Both in silico and experimental results showed that recombinant enolase from H. influenzae is immunogenic that could induce a humoral immune response; this was observed mediating the generation of specific polyclonal antibodies anti-rNTHiENO that recognize typeable and nontypeable H. influenzae strains. The immunogenic properties and the superficial localization of enolase in H. influenzae, important characteristics to be considered as a new candidate for the development of a vaccine, were demonstrated.


Asunto(s)
Proteínas Bacterianas/inmunología , Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/inmunología , Haemophilus influenzae/inmunología , Fosfopiruvato Hidratasa/inmunología , Infecciones del Sistema Respiratorio/prevención & control , Proteínas Bacterianas/genética , Proteínas Bacterianas/aislamiento & purificación , Clonación Molecular , Biología Computacional , Epítopos/genética , Epítopos/inmunología , Infecciones por Haemophilus/inmunología , Infecciones por Haemophilus/microbiología , Vacunas contra Haemophilus/genética , Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae/enzimología , Haemophilus influenzae/genética , Humanos , Fosfopiruvato Hidratasa/genética , Fosfopiruvato Hidratasa/aislamiento & purificación , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/aislamiento & purificación , Infecciones del Sistema Respiratorio/inmunología , Infecciones del Sistema Respiratorio/microbiología , Desarrollo de Vacunas , Vacunas de Subunidad/genética , Vacunas de Subunidad/inmunología , Vacunas de Subunidad/uso terapéutico
2.
Biotechnol Prog ; 33(6): 1508-1519, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-28840658

RESUMEN

Haemophilus influenzae type b (Hib), a Gram-negative capsulated bacterium, is a causative agent of meningitis worldwide. The capsular polysaccharide, a high molecular mass polymer consisting of the repeated units of the polyribosyl-ribitol-phosphate, is considered the main virulence factor and it is used as an antigen to vaccines, conjugated to a carrier protein. The industrial production of the polysaccharide requires the cultivation of Hib in rich medium, which impacts process costs and product recovery. In this study, a central composite rotational experimental design strategy was used to access the influence of key components of culture medium (soy peptone, yeast extract and glucose) on biomass formation and polysaccharide production in shake-flasks. The optimized medium formulation, containing half of the usual yeast extract and soytone concentrations, was further validated in batch bioreactor cultivations. High polysaccharide production (∼500 mg/L) was obtained in a cheaper and more competitive production process for use in Hib vaccine production. In addition, simulations of a metabolic model describing Hib central metabolism were used to assess the role of key amino acids on growth. A chemically defined medium supplemented only with amino acids from α-ketoglutarate and oxaloacetate families as well as phenylalanine was suggested as a promising alternative for reduced acetate accumulation and enhanced polysaccharide production in Hib cultures. © 2017 American Institute of Chemical Engineers Biotechnol. Prog., 33:1508-1519, 2017.


Asunto(s)
Técnicas de Cultivo de Célula/métodos , Vacunas contra Haemophilus/biosíntesis , Haemophilus influenzae tipo b/crecimiento & desarrollo , Polisacáridos/metabolismo , Cápsulas Bacterianas/genética , Cápsulas Bacterianas/metabolismo , Reactores Biológicos , Medios de Cultivo , Vacunas contra Haemophilus/genética , Vacunas contra Haemophilus/metabolismo , Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae tipo b/patogenicidad , Humanos , Meningitis/microbiología , Meningitis/prevención & control , Análisis de Flujos Metabólicos , Polisacáridos/genética , Polisacáridos/inmunología
3.
Vaccine ; 34(4): 404-407, 2016 Jan 20.
Artículo en Inglés | MEDLINE | ID: mdl-26707214

RESUMEN

The use of immunosuppressive drugs can impair vaccination responses. When used during pregnancy, they may interfere with the development of the fetus's immune system. However, little is known regarding their influence on infant's response to vaccinations. Twenty-seven children born to renal transplant mothers (Tx) taking immunosuppressive drugs and 31 healthy children had the humoral immune response and reactogenicity to tetanus, Haemophilus influenzae type b (Hib) and 7 pneumococcal serotypes evaluated. The evolution of BCG vaccine scar was also registered. Antibodies were measured by ELISA. Lymphocyte immunophenotyping was performed on cord blood and at 7-8 months of age. Among Tx neonates, 82.4% had low B lymphocyte numbers at birth, and 29.4% had also low numbers of other lymphocyte subpopulations. Nevertheless, all children developed protective antibodies with similar antibody concentrations to the control group. Vaccine reactogenicity was similar in both groups and BCG healing was uneventful.


Asunto(s)
Inmunidad Humoral , Inmunosupresores/uso terapéutico , Receptores de Trasplantes , Vacunación , Adulto , Anticuerpos Antibacterianos/sangre , Linfocitos B/citología , Cápsulas Bacterianas , Femenino , Sangre Fetal/citología , Vacunas contra Haemophilus/uso terapéutico , Humanos , Lactante , Recién Nacido , Trasplante de Riñón , Madres , Vacunas Neumococicas/uso terapéutico , Embarazo , Complicaciones del Embarazo/epidemiología , Efectos Tardíos de la Exposición Prenatal/epidemiología , Estudios Prospectivos , Adulto Joven
4.
Mem Inst Oswaldo Cruz ; 110(6): 755-9, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26517654

RESUMEN

The aim of the present study was to assess the prevalence of Haemophilus influenzae type b (Hib) nasopharyngeal (NP) colonisation among healthy children where Hib vaccination using a 3p+0 dosing schedule has been routinely administered for 10 years with sustained coverage (> 90%). NP swabs were collected from 2,558 children who had received the Hib vaccine, of whom 1,379 were 12-< 24 months (m) old and 1,179 were 48-< 60 m old. Hi strains were identified by molecular methods. Hi carriage prevalence was 45.1% (1,153/2,558) and the prevalence in the 12-< 24 m and 48-< 60 m age groups were 37.5% (517/1,379) and 53.9% (636/1,179), respectively. Hib was identified in 0.6% (16/2,558) of all children in the study, being 0.8% (11/1,379) and 0.4% (5/1,179) among the 12-< 24 m and 48-< 60 m age groups, respectively. The nonencapsulate Hi colonisation was 43% (n = 1,099) and was significantly more frequent at 48-< 60 m of age (51.6%, n = 608) compared with that at 12-< 24 m of age (35.6%, n = 491). The overall resistance rates to ampicillin and chloramphenicol were 16.5% and 3.7%, respectively; the co-resistance was detected in 2.6%. Our findings showed that the Hib carrier rate in healthy children under five years was very low after 10 years of the introduction of the Hib vaccine.


Asunto(s)
Portador Sano/inmunología , Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae tipo b/inmunología , Nasofaringe/microbiología , Resistencia a la Ampicilina/inmunología , Cápsulas Bacterianas/inmunología , Brasil/epidemiología , Portador Sano/microbiología , Preescolar , Resistencia al Cloranfenicol/inmunología , Estudios Transversales , Infecciones por Haemophilus/epidemiología , Haemophilus influenzae tipo b/clasificación , Humanos , Esquemas de Inmunización , Lactante , Vacunación Masiva , Pruebas de Sensibilidad Microbiana , Reacción en Cadena de la Polimerasa , Prevalencia , Encuestas y Cuestionarios
5.
Mem. Inst. Oswaldo Cruz ; 110(6): 755-759, Sept. 2015. tab
Artículo en Inglés | LILACS, Sec. Est. Saúde SP | ID: lil-763097

RESUMEN

The aim of the present study was to assess the prevalence of Haemophilus influenzaetype b (Hib) nasopharyngeal (NP) colonisation among healthy children where Hib vaccination using a 3p+0 dosing schedule has been routinely administered for 10 years with sustained coverage (> 90%). NP swabs were collected from 2,558 children who had received the Hib vaccine, of whom 1,379 were 12-< 24 months (m) old and 1,179 were 48-< 60 m old. Hi strains were identified by molecular methods. Hi carriage prevalence was 45.1% (1,153/2,558) and the prevalence in the 12-< 24 m and 48-< 60 m age groups were 37.5% (517/1,379) and 53.9% (636/1,179), respectively. Hib was identified in 0.6% (16/2,558) of all children in the study, being 0.8% (11/1,379) and 0.4% (5/1,179) among the 12-< 24 m and 48-< 60 m age groups, respectively. The nonencapsulate Hi colonisation was 43% (n = 1,099) and was significantly more frequent at 48-< 60 m of age (51.6%, n = 608) compared with that at 12-< 24 m of age (35.6%, n = 491). The overall resistance rates to ampicillin and chloramphenicol were 16.5% and 3.7%, respectively; the co-resistance was detected in 2.6%. Our findings showed that the Hib carrier rate in healthy children under five years was very low after 10 years of the introduction of the Hib vaccine.


Asunto(s)
Humanos , Lactante , Preescolar , Portador Sano/inmunología , Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae tipo b/inmunología , Nasofaringe/microbiología , Resistencia a la Ampicilina/inmunología , Cápsulas Bacterianas/inmunología , Brasil/epidemiología , Portador Sano/microbiología , Resistencia al Cloranfenicol/inmunología , Estudios Transversales , Infecciones por Haemophilus/epidemiología , Haemophilus influenzae tipo b/clasificación , Esquemas de Inmunización , Vacunación Masiva , Pruebas de Sensibilidad Microbiana , Reacción en Cadena de la Polimerasa , Prevalencia , Encuestas y Cuestionarios
6.
Cien Saude Colet ; 18(5): 1451-8, 2013 May.
Artículo en Portugués | MEDLINE | ID: mdl-23670473

RESUMEN

This article seeks to analyze and update the epidemiological situation of meningitis caused by Haemophilus influenzae type b in the past 10 years in the state of Rio Grande do Sul (RS). It is a retrospective, descriptive study, which used the data notification system of meningitis and vaccination campaign coverage, stored in the Epidemiological TABNET online database, for the period from 1999 to 2010. Cases notified and confirmed were used and the selection criteria were the year when the symptoms were detected, age, diagnosis, and evolution. Nineteen health centers in the state of Rio Grande do Sul were analyzed. The z-test was used to evaluate comparisons between the proportions. In the period studied, 3043 confirmed cases of bacterial meningitis were reported, of which 6.77% were caused by H. influenzae. The incidence and mortality rates of meningitis caused by H. influenzae, without taking age group into consideration, fell significantly (95.6%) after 1999. Children under one year old continue to be the most affected (52%), there being no change in lethality. The results presented revealed a positive impact of Hib vaccination strategies in the state of Rio Grande do Sul over the past ten years.


Asunto(s)
Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae tipo b , Meningitis por Haemophilus/epidemiología , Meningitis por Haemophilus/prevención & control , Brasil/epidemiología , Preescolar , Humanos , Incidencia , Lactante , Estudios Retrospectivos , Factores de Tiempo
7.
Ciênc. Saúde Colet. (Impr.) ; Ciênc. Saúde Colet. (Impr.);18(5): 1451-1458, Mai. 2013. graf
Artículo en Portugués | LILACS | ID: lil-674759

RESUMEN

O objetivo deste artigo é analisar e verificar a situação epidemiológica das meningites causadas pelo agente Haemophilus influenzae tipo b nos últimos 10 anos no Rio Grande do Sul. Estudo retrospectivo, descritivo, utilizando o sistema de dados de notificação de meningites, e cobertura vacinal, armazenados em base on line Tabnet - Tabulação de dados Epidemiológicos - CEVS/SES/RS, abrangendo o período de 1999 a 2010. Foram utilizados casos notificados e confirmados, tendo como critério de seleção o ano de inicio dos sintomas, idade, diagnostico e evolução. Foi analisado o Estado do Rio Grande do Sul, representado por 19 coordenadorias de saúde. Comparações entre proporções foram avaliadas pelo teste de z. No RS foram notificados 3043 casos confirmados de meningite bacteriana, sendo 6,77% dos casos causados por H. influenzae. O coeficiente de incidência da meningite por H. influenzae, sem considerar faixa etária, caiu significativamente (95,6%) após 1999, assim como a mortalidade. Crianças menores de um ano continuam sendo as mais acometidas (52%), não havendo alteração na letalidade. Os resultados apresentados revelaram um impacto positivo das estratégias de vacinação contra Hib no Estado do Rio Grande do Sul nos últimos dez anos.


This article seeks to analyze and update the epidemiological situation of meningitis caused by Haemophilus influenzae type b in the past 10 years in the state of Rio Grande do Sul (RS). It is a retrospective, descriptive study, which used the data notification system of meningitis and vaccination campaign coverage, stored in the Epidemiological TABNET online database, for the period from 1999 to 2010. Cases notified and confirmed were used and the selection criteria were the year when the symptoms were detected, age, diagnosis, and evolution. Nineteen health centers in the state of Rio Grande do Sul were analyzed. The z-test was used to evaluate comparisons between the proportions. In the period studied, 3043 confirmed cases of bacterial meningitis were reported, of which 6.77% were caused by H. influenzae. The incidence and mortality rates of meningitis caused by H. influenzae, without taking age group into consideration, fell significantly (95.6%) after 1999. Children under one year old continue to be the most affected (52%), there being no change in lethality. The results presented revealed a positive impact of Hib vaccination strategies in the state of Rio Grande do Sul over the past ten years.


Asunto(s)
Preescolar , Humanos , Lactante , Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae tipo b , Meningitis por Haemophilus/epidemiología , Meningitis por Haemophilus/prevención & control , Brasil/epidemiología , Incidencia , Estudios Retrospectivos , Factores de Tiempo
9.
J Pediatr ; 158(6): 996-1002, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21227448

RESUMEN

OBJECTIVES: To determine whether children born in Texas regions with higher vaccination coverage had reduced risk of childhood cancer. STUDY DESIGN: The Texas Cancer Registry identified 2800 cases diagnosed from 1995 to 2006 who were (1) born in Texas and (2) diagnosed at ages 2 to 17 years. The state birth certificate data were used to identify 11 200 age- and sex-matched control subjects. A multilevel mixed-effects regression model compared vaccination rates among cases and control subjects at the public health region and county level. RESULTS: Children born in counties with higher hepatitis B vaccine coverage had lower odds of all cancers combined (OR = 0.81, 95% CI: 0.67 to 0.98) and acute lymphoblastic leukemia (ALL) specifically (OR = 0.63, 95% CI: 0.46 to 0.88). A decreased odds for ALL also was associated at the county level with higher rates of the inactivated poliovirus vaccine (OR = 0.67, 95% CI: 0.49 to 0.92) and 4-3-1-3-3 vaccination series (OR = 0.62, 95% CI: 0.44 to 0.87). Children born in public health regions with higher coverage levels of the Haemophilus influenzae type b-conjugate vaccine had lower odds of ALL (OR: 0.58; 95% CI: 0.42 to 0.82). CONCLUSIONS: Some common childhood vaccines appear to be protective against ALL at the population level.


Asunto(s)
Oncología Médica/métodos , Neoplasias/epidemiología , Neoplasias/prevención & control , Pediatría/métodos , Adolescente , Estudios de Casos y Controles , Niño , Preescolar , Femenino , Vacunas contra Haemophilus/uso terapéutico , Vacunas contra Hepatitis B/uso terapéutico , Humanos , Lactante , Masculino , Oportunidad Relativa , Vacunas contra Poliovirus/uso terapéutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/prevención & control , Análisis de Regresión , Texas , Vacunas/efectos adversos
11.
J Pediatr (Rio J) ; 82(3 Suppl): S109-14, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16826309

RESUMEN

OBJECTIVE: To identify evidence of the impact of Haemophilus influenzae type b (Hib) conjugate vaccine on the epidemiology of invasive Hib disease. SOURCES OF DATA: This review was based on a search of MEDLINE, LILACS, technical reports, national and international guidelines (publications from 1991 to 2005). The keywords Haemophilus influenzae type b, immunization, impact, and effectiveness, alone or in combination, were used to retrieve the articles. Studies published before 1991 and cited in the references of the studies reviewed were analyzed for useful information. SUMMARY OF THE FINDINGS: Introduction of the Hib conjugate vaccine produced great decline in the incidence of invasive Hib disease in childhood in countries where this vaccine was introduced into the routine immunization schedule. Nevertheless, the resurgence of invasive Hib disease in some regions has challenged several researchers to identify the reasons for this epidemiological pattern, as well as the measures to be implemented in order to avoid such a phenomenon. CONCLUSIONS: The use of Hib conjugate vaccine on a population scale has been greatly effective; nonetheless, changes in the vaccination scheme seem to be necessary to keep invasive Hib disease under control.


Asunto(s)
Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae tipo b/inmunología , Programas de Inmunización , Polisacáridos Bacterianos/uso terapéutico , Vacunación , Cápsulas Bacterianas , Salud Global , Infecciones por Haemophilus/complicaciones , Infecciones por Haemophilus/inmunología , Vacunas contra Haemophilus/inmunología , Humanos , Programas de Inmunización/estadística & datos numéricos , Esquemas de Inmunización , Meningitis por Haemophilus/microbiología , Polisacáridos Bacterianos/inmunología , Factores de Tiempo , Vacunación/normas , Vacunación/estadística & datos numéricos , Vacunas Combinadas , Vacunas Conjugadas
12.
J. pediatr. (Rio J.) ; J. pediatr. (Rio J.);82(3,supl): s109-s114, jul. 2006. mapas
Artículo en Portugués | LILACS | ID: lil-433966

RESUMEN

OBJETIVO: Identificar as evidências sobre o impacto da vacina conjugada para Haemophilus influenzae tipo b (Hib) na epidemiologia da doença invasiva por Hib. FONTE DOS DADOS: Pesquisa nas bases de dados do MEDLINE, LILACS, publicações técnicas de organizações internacionais, diretrizes nacionais e internacionais, nos últimos 15 anos (1991-2005), utilizando os seguintes unitermos: Haemophilus influenzae type b, immunization, impact, effectiveness. Foram incluídas as publicações que apresentaram informação para atender o objetivo deste artigo. Artigos publicados em período anterior ao da pesquisa e citados em referências dos artigos incluídos foram analisados quanto à apresentação de informação de interesse. SíNTESE DOS DADOS: A introdução da vacina conjugada para Hib produziu grande declínio na incidência de casos de doença invasiva por Hib nos diversos países em que seu uso foi incorporado à rotina de vacinação das crianças. No entanto, o ressurgimento de casos com doença invasiva por Hib tem mobilizado vários investigadores na busca das possíveis explicações para esses eventos, bem como a identificação das medidas a serem implementadas para evitar o reaparecimento da doença. CONCLUSÕES: O uso da vacina conjugada para Hib em escala populacional tem sido extremamente efetivo. No entanto, mudanças no esquema vacinal poderão ser necessárias para a manutenção do controle da doença invasiva por Hib, frente ao atual cenário epidemiológico das infecções pelo Hib.


Asunto(s)
Humanos , Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae tipo b/inmunología , Programas de Inmunización , Polisacáridos Bacterianos/uso terapéutico , Vacunación , Salud Global , Infecciones por Haemophilus/complicaciones , Infecciones por Haemophilus/inmunología , Vacunas contra Haemophilus/inmunología , Esquemas de Inmunización , Programas de Inmunización/estadística & datos numéricos , Meningitis por Haemophilus/microbiología , Polisacáridos Bacterianos/inmunología , Factores de Tiempo , Vacunas Combinadas , Vacunas Conjugadas , Vacunación/normas , Vacunación/estadística & datos numéricos
13.
Rev. chil. infectol ; Rev. chil. infectol;23(1): 50-54, mar. 2006. tab
Artículo en Español | LILACS | ID: lil-426155

RESUMEN

Tras nueve años desde la introducción en Chile de la vacuna conjugada contra Haemophilus influenzae tipo b (Hib) a las edades de 2-4 y 6 meses, las infecciones por este agente han disminuido notoriamente, pero aún son causa de morbilidad de importancia en algunos pacientes. Se reportan los niños con enfermedad invasora por Hib ocurridas entre los años 2000 y 2004. Para esto se analizaron los egresos del Hospital Padre Hurtado, consignándose epidemiología, clínica, laboratorio, terapia y complicaciones para cada paciente. Durante este período, 23 pacientes (17 varones), con una mediana de edad de 30 meses (rango 1-71 meses) presentaron enfermedad invasora por Hib. Estas se presentaron como neumonía (7), meningitis (4), pleuroneumonía (2), empiema pleural (2), sepsis (2), celulitis (2), meningitis y pleuroneumonía (1), purpura fulminans (1), miositis (1) y epiglotitis (1). No se registraron fallecimientos, pero 4 pacientes presentaron secuelas graves al momento del alta. Veinte pacientes fueron catalogados como falla de vacuna. Hamophilus influenzae b es aún un agente causal de enfermedad grave y con morbilidad asociada en nuestro país, por lo que es importante tener un alto índice de sospecha. Su estudio y notificación son relevantes para la evaluación del esquema de vacunación anti-Hib actualmente utilizado.


Asunto(s)
Masculino , Humanos , Femenino , Lactante , Preescolar , Niño , Haemophilus influenzae tipo b , Programas de Inmunización , Infecciones por Haemophilus/complicaciones , Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/uso terapéutico , Chile , Farmacorresistencia Microbiana , Evaluación de Resultados de Acciones Preventivas , Infecciones por Haemophilus/sangre , Vacunación Masiva , Pruebas de Sensibilidad Microbiana , Meningitis/microbiología , Neumonía/microbiología , Portador Sano/microbiología , Estudios Retrospectivos , Vacunas Conjugadas
14.
Int J Epidemiol ; 33(1): 173-81, 2004 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-15075166

RESUMEN

BACKGROUND: The conjugate Haemophilus influenzae type b (Hib) vaccine has been highly efficacious in reducing type b H. influenzae meningitis. However, information is limited about its impact on childhood pneumonia after vaccine introduction into the routine programme. This study evaluated the effectiveness of Hib conjugate vaccine in the reduction of community-acquired pneumonia among infants in Central Brazil. METHODS: A matched case-control study was built into an ongoing prospective population-based surveillance of pneumonia, enrolling 1293 participants between May 2000 and August 2001. Cases (n = 431) were children

Asunto(s)
Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae tipo b/inmunología , Neumonía Bacteriana/prevención & control , Distribución por Edad , Brasil/epidemiología , Estudios de Casos y Controles , Guarderías Infantiles , Preescolar , Femenino , Infecciones por Haemophilus/epidemiología , Humanos , Lactante , Masculino , Neumonía Bacteriana/epidemiología , Vigilancia de la Población/métodos , Estudios Prospectivos , Factores de Riesgo , Resultado del Tratamiento , Vacunas Conjugadas/uso terapéutico
15.
J Pediatr ; 143(6 Suppl): S163-87, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14657805

RESUMEN

On September 22 to 25, 2002, a group of infectious disease specialists, public health officials, and vaccine experts from 33 countries gathered in Scottsdale, Arizona, to discuss the epidemiology and control of disease caused by Haemophilus influenzae type b (Hib) in the era of Hib conjugate vaccines. This supplement is a synthesis of the major themes and key lessons identified at the meeting. The objectives of the conference were to review the 10-year experience with Hib conjugate vaccines, discuss strategies to reduce Hib disease rates to lowest possible levels in industrialized countries, review impediments to the introduction of Hib vaccine in developing countries, and discuss strategies for disseminating lessons learned from countries using to those not using Hib conjugate vaccines. Over 10 years of international experience with Hib conjugate vaccines has demonstrated that they are safe and effective. Routine use of Hib conjugate vaccine has consistently led to decreases in the incidence of invasive Hib disease of 90% or more across a wide range of epidemiologic situations in industrialized countries. In some countries, the vaccine has caused a near-disappearance of invasive Hib disease through a combination of direct protection and herd immunity. Developing countries that have implemented routine vaccination (eg, The Gambia, Chile) have also had substantial disease reduction. In countries where Hib conjugate vaccine is being used, reducing Hib disease incidence to the lowest possible level will depend on maintaining high vaccine coverage levels, conducting surveillance for Hib disease, and investigating Hib disease cases. The optimal Hib vaccination strategy will depend on many factors, including local epidemiology and programmatic considerations. In countries that are not using Hib conjugate vaccine, information on the local burden of Hib disease will be essential for leaders considering vaccine introduction. Where disease burden is high, a multifaceted approach is urgently needed to evaluate and overcome barriers to vaccine introduction. In areas where Hib disease burden is not well characterized, additional work will be needed to understand the epidemiology of Hib disease and to communicate the value of Hib conjugate vaccine.


Asunto(s)
Salud Global , Infecciones por Haemophilus/inmunología , Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae/inmunología , Meningitis por Haemophilus/inmunología , Neumonía Bacteriana/inmunología , Niño , Países en Desarrollo , Infecciones por Haemophilus/diagnóstico , Infecciones por Haemophilus/epidemiología , Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/economía , Humanos , Programas de Inmunización/organización & administración , Meningitis por Haemophilus/diagnóstico , Meningitis por Haemophilus/epidemiología , Meningitis por Haemophilus/prevención & control , Neumonía Bacteriana/diagnóstico , Neumonía Bacteriana/epidemiología , Neumonía Bacteriana/prevención & control , Vacunas Combinadas/uso terapéutico , Vacunas Conjugadas/economía , Vacunas Conjugadas/uso terapéutico
16.
Braz J Infect Dis ; 7(5): 315-24, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-14552741

RESUMEN

Acute bacterial meningitis is an important cause of morbidity and mortality among children less than five years old, Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis being the most important agents of bacterial meningitis in developing countries. The development of the conjugate vaccines in the beginning of the 90's, especially type b H. influenzae (Hib), and more recently the heptavalent pneumococcal and the serogroup C meningococcal vaccines, have contributed directly to changes in the epidemiological profile of these invasive diseases (direct effect) and of their carriage status (indirect effect). We review the impact of the Hib conjugate vaccine in Latin American countries, where this vaccine has been implemented, and the potential of pneumococcal and meningococcal conjugate vaccines for the reduction of meningitis worldwide. We also address constraints for the development and delivery of these vaccines and review new candidate state-of-the-art vaccines. The greatest challenge, undoubtedly, is to implement these vaccines worldwide, especially in the developing regions.


Asunto(s)
Vacunas Bacterianas/uso terapéutico , Meningitis Bacterianas/prevención & control , Cápsulas Bacterianas , Niño , Vacunas contra Haemophilus/uso terapéutico , Humanos , Incidencia , América Latina/epidemiología , Meningitis Bacterianas/epidemiología , Vacunas Meningococicas/uso terapéutico , Vacunas Neumococicas/uso terapéutico , Polisacáridos Bacterianos/uso terapéutico , Vacunas Conjugadas/uso terapéutico
17.
Antimicrob Agents Chemother ; 46(11): 3641-3, 2002 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12384381

RESUMEN

Antimicrobial susceptibility was determined for 150 Haemophilus influenzae isolates obtained during population-based surveillance for meningitis in Salvador, Brazil. Ten (6.7%) isolates were resistant to ampicillin and chloramphenicol. Of these, two isolates, a beta-lactamase and non-beta-lactamase producer, were resistant to amoxacillin-clavulinic acid. These findings indicate that present antibiotic regimens in Brazil may not be appropriate for the treatment of H. influenzae meningitis.


Asunto(s)
Haemophilus influenzae/efectos de los fármacos , Meningitis por Haemophilus/microbiología , Combinación Amoxicilina-Clavulanato de Potasio/farmacología , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Brasil/epidemiología , Análisis Costo-Beneficio , Farmacorresistencia Bacteriana , Farmacorresistencia Bacteriana Múltiple , Quimioterapia Combinada/farmacología , Quimioterapia Combinada/uso terapéutico , Vacunas contra Haemophilus/economía , Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae/enzimología , Humanos , Meningitis por Haemophilus/epidemiología , Meningitis por Haemophilus/prevención & control , Pruebas de Sensibilidad Microbiana , Vigilancia de la Población , beta-Lactamasas/metabolismo
18.
Microb Drug Resist ; 8(1): 67-72, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12002652

RESUMEN

The Haemophilus influenzae serotype b (Hib) conjugate vaccine was introduced in the National Immunization Program in Brazil in the second half of 1999. A retrospective analysis on serotypes, biotypes, and antimicrobial resistance of Hi invasive strains obtained through Hi survey was conducted to document the characteristics of this pathogenic agent during a decade prior the use of Hib vaccine. A total 3,204 strains from 1990 to 1999 were studied, being 88.2% isolated from cerebrospinal fluid, 10.7% from blood, and 1.1% from pleural fluid. The rate of 90.9% of strains was obtained from children up to 4 years old, and the age group >6 months old to 1 year was the higher risk to Hi infection. Type b was, by far, the most common type (97.8%), followed in frequency by type a (0.5%); only 1.5% was a nontypable strain. Biotypes I and II accounted for 97.8% of isolates. Resistance to ampicillin (AM) and chloramphenicol (CO) was detected at rates of 18.1% and 19.1%, respectively, whereas simultaneous resistance to AM and CO was identified in 13.9% of strains. Total concordance was found between AM resistance and beta-lactamase production. No strain showed resistance to ceftriaxone and rifampicin. In conclusion, the data generated through this laboratory-based surveillance should serve as a reference for assessing the impact of Hib vaccination and to detect changes on the pattern of Hi diseases in the country.


Asunto(s)
Infecciones por Haemophilus/microbiología , Haemophilus influenzae tipo b/efectos de los fármacos , Adolescente , Adulto , Factores de Edad , Anciano , Antibacterianos/farmacología , Técnicas Bacteriológicas , Brasil/epidemiología , Niño , Preescolar , Farmacorresistencia Microbiana , Femenino , Infecciones por Haemophilus/epidemiología , Infecciones por Haemophilus/inmunología , Vacunas contra Haemophilus/uso terapéutico , Humanos , Lactante , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos , Serotipificación , Vacunación , Vacunas Conjugadas/uso terapéutico
19.
Rev Med Chil ; 129(7): 719-26, 2001 Jul.
Artículo en Español | MEDLINE | ID: mdl-11552439

RESUMEN

BACKGROUND: Acute bacterial meningitis still has a high mortality and rate of complications. AIM: To assess the impact of anti H influenzae vaccination on the epidemiology of acute bacterial meningitis in Chilean children. MATERIAL AND METHODS: A retrospective study of hospital discharge records of patients with acute bacterial meningitis. Causative agents were studied globally, by hospital and by age group. The changes in etiology from 1989 to 1995 were also assessed. Between 1996 and 1998, only those patients with acute bacterial meningitis caused by H influenzae were recollected. RESULTS: In the period prior to vaccination (1989-1995), 1000 cases were registered. The main causative agents were N meningitidis in 33.8%, H influenzae type b in 21.9% and S pneumoniae in 15.4%. The incidence of H influenzae decreased in the period from 36.4 to 9.9% (p < 0.001) and the incidence of N meningitidis increased from 22.9 to 52.1% (p < 0.001). The incidence of S pneumoniae did not change significantly. H influenzae predominated in children between 4 and 24 months of age and N meningitidis predominated in children over 25 months of age. In the period after the introduction of vaccination (1995-1998), there was a further decrease in the incidence of H influenzae from 10 to 2% (p < 0.001). Until 1997, there was a considerable increase in the incidence of N meningitidis, specially in children over 25 months of age. It declined in 1998 to 38%. CONCLUSIONS: There was a reduction in the incidence of acute bacterial meningitis caused by H influenzae prior to the introduction of the vaccine against H influenzae type b. The decrease was more pronounced after the introduction of the vaccine.


Asunto(s)
Vacunas contra Haemophilus/uso terapéutico , Haemophilus influenzae tipo b/aislamiento & purificación , Meningitis Bacterianas/epidemiología , Meningitis Bacterianas/microbiología , Enfermedad Aguda , Adolescente , Adulto , Niño , Preescolar , Chile/epidemiología , Haemophilus influenzae tipo b/inmunología , Humanos , Incidencia , Lactante , Recién Nacido , Meningitis Bacterianas/prevención & control , Estudios Retrospectivos
20.
Rev Saude Publica ; 35(3): 249-55, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11486147

RESUMEN

OBJECTIVE: To document the incidence and the descriptive epidemiology of bacterial meningitis among individuals under age 20 in a geographically defined region in Brazil during the two-year period immediately preceding the introduction of Haemophilus influenzae type b (Hib) vaccines into the national immunization program of Brazil. METHODS: Population-based epidemiological study of all cases of bacterial meningitis reported among residents of Campinas, Brazil, under age 20 (n=316,570) during the period of 1997-98, using comprehensive surveillance records compiled by the Campinas Health Department from cases reported among hospital inpatients, outpatients, emergency room visits, death certificates, and autopsy reports. RESULTS: The incidence of bacterial meningitis (n=274) was 334.9, 115 and 43.5 cases/10(5) person-years (pys) for residents of Campinas under age 1, 5 and 20, respectively. All cases were hospitalized, with an average length of stay of 12 days. Documented prior antibiotic use was 4.0%. The case-fatality rate of bacterial meningitis in individuals under age 20 was 9% (24/274) with 75% of deaths occurring in children under the age of five. The incidence of Hib meningitis (n=26) was 62.8 and 17 cases/10(5) pys in children age <1 and <5, respectively. CONCLUSIONS: The incidence of Hib meningitis in children under the age of 5 in Campinas during 1997-98 was similar to that reported in the US, Western Europe, and Israel prior to widespread Hib vaccine use in those regions. This study provides a baseline for later studies to evaluate changes in the etiology and incidence of bacterial meningitis in children after introduction of routine Hib vaccination in Brazil.


Asunto(s)
Meningitis Bacterianas/epidemiología , Adolescente , Adulto , Distribución por Edad , Antibacterianos/uso terapéutico , Brasil/epidemiología , Niño , Preescolar , Femenino , Vacunas contra Haemophilus/uso terapéutico , Humanos , Incidencia , Lactante , Recién Nacido , Masculino , Meningitis Bacterianas/tratamiento farmacológico , Meningitis Bacterianas/mortalidad , Distribución por Sexo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA